SARS-CoV-2 spike – Page 40 – Communicable Diseases Research

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

SARS-CoV-2 스파이크 결실 H69/V70의 반복적인 출현과 알파 변이체 B.1.1.7에서의 역할

Article

Published on 2021-06-082022-09-11
Journal: Cell Reports [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단,

Engineering of Chinese Hamster Ovary Cells With NDPK-A to Enhance DNA Nuclear Delivery Combined With EBNA1 Plasmid Maintenance Gives Improved Exogenous Transient Reporter, mAb and SARS-CoV-2 Spike Protein Expression

Bioengineering and Biotechnology

Published on 2021-06-042022-10-31
Journal: Frontiers in Bioengineering and Biotechnology [Category] COVID-19,

[키워드] approach cell line characterisation Chinese Chinese hamster ovary cells CHO cells co-expression Combined complementary complex delivery dependent on Dilution DNA Efficiency element Engineering ENhance Epstein Barr Nuclear Antigen-1 Exogenous expressing Gene Expression glycoprotein growth hamster Improved initial mAb maintenance mammalian cell membranes NLS nuclear nuclear localisation signal nucleoside diphosphate kinase nucleus Ovary plasma Plasmid Protein reduce SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein spike time-consuming Transient transient expression transient gene expression utilised
[DOI] 10.3389/fbioe.2021.679448 PMC 바로가기 [Article Type] Bioengineering and Biotechnology

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern

우려되는 SARS-CoV-2 변이체에 대한 중화 항체의 에피토프 분류 및 RBD 결합 특성

Immunology

Published on 2021-06-042022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단,

[키워드] ACE2 ACE2 binding ACE2 binding affinity acute respiratory syndrome acute respiratory syndrome coronavirus Against Analysis angiotensin angiotensin converting enzyme antibody bind binding binding affinity binding epitope C1D cause Cell classification concern coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID19 death disease disrupting E484K ENhance enzyme epitope mapping Epitopes evade evaluated exhibited Host immune response hosts interactions L452R less mutant N501Y NAb NAbs Naturally Neutralizing antibodies neutralizing antibody P.1 predict promote property Protein quantified RBD RBD binding RBD variant RBD variants Receptor binding domain representing respiratory responsible SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 spike SARS-CoV-2 WT sensitivity sequence variation Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 spike Strains surface area susceptible susceptible hosts the RBD the SARS-CoV-2 therapeutic option Treatment variant variant of concern Viral viral infectivity viral pathogenesis while Wuhan-1
[DOI] 10.3389/fimmu.2021.691715 PMC 바로가기 [Article Type] Immunology

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Research Article

Published on 2021-06-022022-10-30
Journal: mSphere [Category] COVID-19,

[키워드] antibody Antibody titer Antibody titers approved Blood booster calculated can be used caused Cell clinical clinical samples clinical specificity Clinical use clinical validation Concentration correlated country COVID-19 COVID-19 vaccines Critical death determinant development disease displaying dosing schedule elicit feasibility FIVE future infection gold standard high-throughput assay human serum Infection infections limit limit of detection measure monoclonal antibody Neutralizing antibodies neutralizing antibody Neutralizing antibody response Neutralizing antibody titer parameter performed plaque-reduction neutralization test plasma Precision Prevent protective immune response question required SARS-CoV-2 SARS-CoV-2 immunity SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike glycoprotein SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody sensitivity standard curve strong immune response surrogate virus titer turn utility vaccinated individual vaccinated individuals vaccination Vaccine Vaccine-induced immunity validation vesicular stomatitis virus virus virus assay widespread
[DOI] 10.1128/mSphere.00170-21 PMC 바로가기 [Article Type] Research Article

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

암 환자를 위한 COVID-19 백신 BNT162b2의 1회 투여 대 2회 투여의 안전성 및 면역원성: 전향적 관찰 연구의 중간 분석

Observational Study

Published on 2021-06-012022-09-10
Journal: The Lancet. Oncology [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI Administered All participant All participants analysed analyses anti-S IgG antibody available data Blood blood sample Blood samples BNT162b2 BNT162b2 vaccine boost Cancer Cancer Research UK Cohort college COVID-19 COVID-19 vaccine Data analysis death dose Efficacy Efficacy and safety eight Endpoint enrolled Evidence evidence of exclusion finding first dose first vaccination FIVE Follow-up Francis Crick funding Haematological cancer Health and Care Research Wales Health Research Authority health-care healthy control healthy controls healthy controls; hospital immunogenicity immunogenicity analysis injection Injection-site pain interim analysis intramuscularly King local reaction London nasopharyngeal NHS observational study of BNT162b2 Pain participant Patient Patients with cancer patients with haematological Pfizer–BioNTech positive profile proportion prospective observational study Protein real-time RT-PCR REC receive recruited Registered reported rRT-PCR Safety SARS-CoV-2 SARS-CoV-2 spike second dose Seroconversion seropositive significantly single vaccine solid cancer Support Swab test symptomatic symptomatic COVID-19 the patient titre toxicities Toxicity Trust vaccination Vaccine Wellcome Trust
[DOI] 10.1016/S1470-2045(21)00213-8 PMC 바로가기 [Article Type] Observational Study

Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study

투석 환자에서 mRNA 또는 벡터 기반 SARS-CoV-2 백신 1차 접종의 면역원성: 다기관 전향적 관찰 파일럿 연구

Observational Study

Published on 2021-05-292022-09-10
Journal: Journal of Nephrology [Category] MERS, SARS, 임상, 치료법,

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

SARS-CoV-2는 항체 면역을 피하기 위해 헴 대사 산물을 모집할 수 있습니다

Research Article

Published on 2021-05-282022-09-12
Journal: Science Advances [Category] SARS, 진단,

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19)

소아 다기관 염증 증후군(MIS-C) 및 경증 및 중증 코로나바이러스 질환 2019(COVID-19) 소아의 중증 급성 호흡기 증후군-코로나바이러스-2(SARS-CoV-2) 항체 반응

Article

Published on 2021-05-282022-09-12
Journal: Journal of the Pediatric Infectious Diseases Socie [Category] SARS, 진단,

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

암 치료를 받는 환자에서 SARS-CoV-2에 대한 BNT162b2 메신저 RNA 백신 접종 후 혈청 양성 평가

Research

Published on 2021-05-282022-09-12
Journal: JAMA Oncology [Category] MERS, SARS, 진단,

[키워드] 95% CI accompanied active treatment age analyses Analysis analyzed anti-S Antibody Response Antibody titer anticancer Beilinson Hospital blood sample Blood samples BNT162b2 BNT162b2 vaccine Cancer center Chemotherapy cohort study comparison Comparisons conducted Control control group COVID-19 COVID-19 disease Davidoff defined develop domain Enrollment evaluate exhibited Factor finding greater healthy control healthy controls high risk higher risk IgG IgG antibodies IgG antibody IgG titer IgG titers immunoassay Immunotherapy Importance intravenous measure median men messenger Messenger RNA multivariable analyses multivariable analysis objective outcome participant Participants Patient Patients with cancer Point Primary outcome prospective cohort study receiving Relevance required Research respond Result RNA SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose second messenger secondary Secondary outcomes seropositive Seropositivity serum sample serum samples setting severe COVID-19 disease significantly significantly lower solid tumor solid tumors Study participants Support systemic therapy systemic treatment the patient therapy titers Treatment Tumor tumors vaccination vaccine dose
[DOI] 10.1001/jamaoncol.2021.2155 PMC 바로가기 [Article Type] Research

Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2’s pathogenicity factors

Research Article

Published on 2021-05-272022-10-28
Journal: PLoS ONE [Category] COVID-19, SARS,

[키워드] 6M0J Analysis antibody bacterial cell binding carried computational analysis cough D614G domain ectodomain effective evade Factor Fever Host immune response immune system induce Infection inhibit manipulative MERS mimicking molecular molecular docking molecular docking analysis molecular dynamics mutant Mutation neutralizing antibody not affected nucleocapsid occurred pandemic pathogenicity performed Predictive protease Protein protein-ligand interaction Proteins Receptor binding domain responsible SARS-CoV-2 SARS-CoV-2 protein SARS-CoV-2 S SARS-CoV-2 spike selected Severe case severe respiratory illness Shortness of breath shown Staphylococcus aureus supported Symptom temperature the SARS-CoV-2 virus trimer virus
[DOI] 10.1371/journal.pone.0252571 PMC 바로가기 [Article Type] Research Article